Cannabidiol, or CBD, is a component of the cannabis plant lacking the “high” associated with marijuana, and right now products claiming to contain CBD are everywhere — from gummies to cocktails, ice cream to hand cream, and more. An estimated 64 million consumers, according to a January 2019 Consumer Reports survey, have tried products containing CBD in the past two years alone. But do you know what you are buying - and taking?
(BPT) - Before you reach into that jar of CBD gummies, or add some CBD oil to your bath, proceed carefully. Do you really know what’s in that “miracle cure” that you purchased online or at the health store for anxiety or your aching back?
Cannabidiol, or CBD, is a component of the cannabis plant lacking the “high” associated with marijuana, and right now products claiming to contain CBD are everywhere — from gummies to cocktails, ice cream to hand cream, and more. An estimated 64 million consumers, according to a January 2019 Consumer Reports survey, have tried products containing CBD in the past two years alone.
With widespread marketing that is largely unregulated, CBD purchased online or at stores is often promoted as a one-stop product for a range of potential health benefits, such as relieving stress, soothing aches and pains, reducing inflammation or improving sleep.
Interest in — and access to — CBD increased with the passage of the Farm Bill which removed CBD derived from hemp (a variety of cannabis that contains very low levels of tetrahydrocannabinol or THC) from the list of controlled substances. Although CBD products are now available online or in many stores, health or medical claims made by the product manufacturers are still subject to regulation by the FDA to ensure consumer safety. Through all the current interest surrounding CBD one critical question remains: Are widely available CBD products safe and effective?
Separating fact from fiction
The contents and dosage of CBD products sold in retail stores or online are often unknown and not consistently, if at all, regulated. To navigate the current environment, consumers first need to understand that not all CBD products are equal:
So, what’s the bottom line for the millions of people currently using CBD products? As the saying goes, the smart consumer is the wise consumer. The FDA approval process is considered by many to be the gold standard in the medical field and was put in place to protect patients. Taking unregulated CBD products that lack scientific evidence can pose health risks, particularly for very sick patients who may be looking for hope in these products, in part, because of unproven health claims.
You deserve to know what you’re taking
It can be difficult to know if CBD products actually contain what they claim. A 2017 study published in the Journal of the American Medical Association found that almost 70% of all CBD products sold online did not contain the amount of CBD stated on the label — 42% contained a higher concentration of CBD than the label claimed, and 26% of the products contained less. Twenty percent included enough unlabeled THC to cause intoxication, especially in children. The FDA also evaluated some of these products and found that they did not contain the levels of CBD that they claimed. More studies and regulations are needed to ensure these products are safe for consumer use.
An important moment in the evolution of CBD occurred in June 2018 when the FDA approved Epidiolex® (cannabidiol) oral solution CV, the first prescription CBD medicine. Because it is a prescription, available in pharmacies just like any other FDA-approved medicine, it is legal throughout the entire U.S. when prescribed by a licensed health care professional. It is the only FDA-approved CBD product currently available.
“The approval of Epidiolex is historic not only for the long-awaited relief it provides patients with Lennox-Gastaut syndrome and Dravet syndrome, two very difficult-to-treat epilepsies, but also for the parameters it has put in place for how a CBD medicine should be studied to understand its safety profile and efficacy,” said Justin Gover, CEO of GW Pharmaceuticals, plc, the company responsible for Epidiolex. “We hope that this opens the door for further well-controlled clinical studies of CBD in other medical conditions to achieve FDA approval and ensure patients are getting the medicines they deserve.”
This sponsored article is presented by Brandpoint.
Although rare cancers don’t occur often, they can affect people of all ages and genders. Greater awareness of rare cancers may lead to earlier diagnosis and management, and potentially better survival rates. Consider these facts about soft tissue sarcomas, one type of rare cancer.
Understanding Rare Cancers
Four facts to know about one type of rare cancer, soft tissue sarcomas
(Family Features) Although rare cancers don’t occur often, they can affect people of all ages and genders.
A rare cancer is defined as fewer than 15 new diagnoses per 100,000 people per year, according to the National Cancer Institute (NCI). Additionally, as noted by the American Cancer Society (ACS), the 5-year survival rate is lower for people diagnosed with a rare cancer than for people living with more common cancers. Greater awareness of rare cancers may lead to earlier diagnosis and management, and potentially better survival rates.
If you have recently been diagnosed with STS, it’s important to ask your doctor for more information about the specific sub-type you have. For example, if you received a diagnosis of undifferentiated sarcoma, ask your doctor for an integrase interactor-1 (INI1) test to see if you have a rare STS called epithelioid sarcoma (ES). (See sidebar for more on ES.)
Learning More About Epithelioid Sarcoma
A rare type of STS, epithelioid sarcoma (ES) accounts for less than 1% of all STS, which themselves account for approximately 1% of all cancers, according to research published in “Archives of Pathology & Laboratory Medicine.” ES can present as a lump or sore on the skin.
Notably, more than 90% of ES tumors do not express the INI1 protein, which when present acts to suppress tumor growth. INI1 loss plays an important role in the diagnosis of ES, according to researchers with “The American Journal of Surgical Pathology.”
Data from the NCI indicates that approximately 150-200 people in the United States are diagnosed with ES each year. Research published in “The Journal of Clinical and Aesthetic Dermatology” found the disease often occurs in young adults in their 20s and 30s. Because most ES patients are adolescents and young adults, there is a gap in the unique psycho-social needs for this patient population, including resources for patients who miss school while undergoing treatments, as well as fertility considerations later in life.
If you or someone you love is living with ES, you can find resources, information and the real-life perspective of an ES survivor at ESsentialsforES.com.
Content courtesy of Epizyme, Inc.
Photo courtesy of Getty ImagesSOURCE:
(BPT) - Each year, more people die of lung cancer than any other form of cancer — more than colon, breast and prostate cancers combined. The American Cancer Society estimates of the 224,000 new cases of lung cancer diagnosed each year, 155,000 will succumb to the disease.
Many have heard the statistics about lung cancer, but for those who have lived through it, or who have a friend or loved one battling the disease, these numbers are even more personal and frightening. The low five-year survival rate (five to 14 percent) for late-stage lung cancer patients makes the search for a way to treat this deadly disease all the more urgent.
To beat cancer, early detection is critical. Scientific research over the past several decades has revealed that cancer is a disease primarily caused by changes — or mutations — in the genes. This discovery has led to a major shift in how early cancer can be detected and treated. Now, researchers are able to identify mutations in the genetic code that are most likely to cause potentially deadly cancers. This has led to the development of new testing technology and drugs that target those specific mutations.
This approach is in stark contrast to traditional detection methods that are limited in their ability to test for a small number of specific mutations linked to only one possible treatment. This painstakingly long process can take several weeks to identify an effective treatment.
In a matter of days, modern techniques using next-generation sequencing technology can save valuable time by avoiding the need to run multiple tests by simultaneously screening tumor samples for multiple mutations and multiple potential therapies. The new technology also reduces the likelihood of subjecting patients to unnecessary and invasive secondary biopsy procedures.
New advancements in early detection and treatment
The U.S. Food and Drug Administration (FDA) recently approved the Oncomine(TM) Dx Target Test, a first-of-its-kind genetic screening solution that can detect multiple gene mutations associated with non-small cell lung cancer (NSCLC) from a single tissue sample. The test has also been approved to aid in selecting which specific FDA-approved NSCLC treatment the patient may be eligible for.
Take action and talk to your doctor
A recent survey by the Journal of Precision Medicine showed that only about a third of patients and caregivers had a good understanding of genomic tools for cancer detection. That’s why talking to a doctor, loved ones and others about new techniques like sequencing-based tests to help inform more effective treatment options is important. Doctors and healthcare networks have a responsibility to their patients to provide the most effective innovations so patients receive the best care possible.
Interested in Publishing on The Health IDEA?
Send your query to the Publisher today!